BMP4-GPX4 Axis Protects Retinal Ganglion Cells in Glaucoma Models

Study Background and Research Question

Glaucoma, a leading cause of irreversible blindness worldwide, is characterized by the progressive degeneration of retinal ganglion cells (RGCs) often triggered by elevated intraocular pressure (IOP). While cell loss is multifactorial, mounting evidence implicates ferroptosis—a regulated, iron-dependent form of cell death driven by oxidative stress—as a central mechanism in RGC vulnerability. Recent advances in regenerative medicine suggest that retinal stem cell (RSC) transplantation could replenish lost RGCs, but the efficiency of this strategy is limited by the survival and differentiation capacity of transplanted cells. The reference study (Fang et al., 2025) investigates whether modulation of the BMP4-GPX4 signaling axis can mitigate ferroptosis and improve RGC survival and differentiation after RSC transplantation in a mouse model of high IOP glaucoma.

Key Innovation from the Reference Study

The central innovation of this study lies in the demonstration that activation of the BMP4-GPX4 pathway not only reduces the ferroptotic phenotype in injured RGCs but also enhances the differentiation potential of transplanted RSCs into functional RGCs. Specifically, the authors link upregulation of BMP4 and its downstream effector GPX4 to improved redox homeostasis and neuroprotection in the glaucomatous retina. This dual mechanism—simultaneous mitigation of iron-mediated oxidative injury and promotion of stem cell fate commitment—offers a compelling therapeutic strategy for glaucomatous neurodegeneration (Fang et al., 2025).

Methods and Experimental Design Insights

To model excitotoxic and ferroptotic injury typical of glaucoma, the researchers used NMDA (N-Methyl-D-aspartic acid) to induce acute RGC damage in mice. NMDA is a well-characterized NMDA receptor agonist that reliably produces excitotoxic stress, calcium influx, and downstream oxidative injury, making it a gold-standard tool for neurodegenerative disease modeling (NMDA: Precision Agonist for Excitotoxicity). Following model establishment, the team assessed BMP4 and GPX4 expression via qPCR and Western blotting, and tracked key ferroptosis markers such as ROS, glutathione (GSH), malondialdehyde (MDA), and Fe²⁺ levels. Immunofluorescence detection of the Brn3a marker confirmed RGC loss and functional impairment post-NMDA. Bioinformatic enrichment analyses (via GEO datasets) identified upregulation of stem cell pluripotency pathways and BMP4 signaling, supporting subsequent mechanistic investigations. Finally, the effects of BMP4-GPX4 modulation on RSC transplantation efficiency and RGC differentiation were systematically evaluated.

Core Findings and Why They Matter

The study revealed several key findings:

• NMDA-induced glaucoma model validation: Mice administered NMDA exhibited decreased Brn3a expression and impaired visual function, confirming robust RGC injury (Fang et al., 2025).
• Ferroptotic stress elevation: Markers of oxidative stress (high ROS, low GSH, elevated MDA, and Fe²⁺) were significantly increased in the glaucoma model, alongside upregulation of ferroptosis markers such as ACSL4 and downregulation of protective GPX4.
• BMP4-GPX4 axis activation: Both bioinformatics and experimental validation revealed increased BMP4 and downstream SMAD1/3/5 signaling, with subsequent enhancement of GPX4 expression, a key antioxidant enzyme.
• Neuroprotection and differentiation: Upregulation of BMP4-GPX4 not only reduced ferroptotic stress but also promoted the differentiation of transplanted RSCs into mature, Brn3a-positive RGCs, suggesting enhanced therapeutic potential for stem cell-based retinal repair.

By directly linking BMP4-GPX4 signaling to both RGC protection and improved stem cell integration, the study identifies a dual-action strategy to address two major challenges in glaucoma therapy: mitigating cell death and promoting regeneration.

Comparison with Existing Internal Articles

The use of NMDA to induce excitotoxicity and model neurodegenerative pathways is well supported in the research literature. Internal resources such as NMDA: Precision Agonist for Excitotoxicity and Unveiling Neurodegeneration Mechanisms provide detailed discussion on how NMDA-induced calcium influx and oxidative stress assays are foundational for studying neuronal death in disease models. Notably, the reviewed paper builds on this paradigm by integrating ferroptosis readouts into the assessment of NMDA-induced damage, thus extending conventional excitotoxicity research with a focus on iron-dependent oxidative mechanisms.

Additionally, an internal review (BMP4-GPX4 Axis Mitigates Ferroptosis) echoes the present findings, emphasizing the pathway’s role in reducing oxidative injury and supporting stem cell differentiation in similar mouse models. The present study distinguishes itself by providing direct experimental links between BMP4-GPX4 modulation and RSC-derived RGC maturation, reinforcing and extending prior mechanistic insights.

Limitations and Transferability

While the BMP4-GPX4 axis shows clear promise in the acute NMDA-induced mouse glaucoma model, several limitations must be acknowledged. First, mouse models may not recapitulate the full complexity or chronic progression of human glaucoma, and NMDA-induced injury, while reproducible, may not capture all aspects of disease etiology. Second, the translation of RSC transplantation protocols from rodents to primates or humans involves significant challenges, including immune compatibility, integration, and long-term functional outcomes. Finally, while BMP4-GPX4 upregulation proved beneficial in this context, the pathway’s effects in other neurodegenerative or retinal disorders require further validation. The study’s methodical combination of excitotoxicity research and ferroptosis assays, however, provides a robust workflow template for broader application in neuroprotection and regenerative strategies.

Protocol Parameters

• NMDA administration for glaucoma model induction: Use intravitreal NMDA injection in mice (typical dose: 10–20 nmol in 2 μL per eye), as reported in Fang et al., 2025, to induce acute RGC injury and model high IOP glaucoma.
• Immunofluorescence for RGC loss: Detect Brn3a expression 2–7 days post-injection to assess RGC damage and validate model establishment.
• Oxidative stress and ferroptosis assays: Quantify ROS, GSH, MDA, and Fe²⁺ levels using standard colorimetric or fluorescence-based kits; assess GPX4 and ACSL4 by Western blot.
• Stem cell transplantation: Inject cultured retinal stem cells into the vitreous or subretinal space after NMDA-induced injury; track differentiation by Brn3a immunostaining.
• BMP4-GPX4 modulation: Manipulate BMP4 signaling via recombinant protein administration or genetic overexpression, and confirm downstream GPX4 expression in target tissues.

Research Support Resources

For researchers aiming to replicate or extend these workflows, high-purity NMDA (N-Methyl-D-aspartic acid) (SKU B1624) from APExBIO provides a validated agonist for inducing excitotoxic and oxidative stress in RGCs, supporting both ferroptosis and neurodegenerative disease model development. As highlighted in recent literature, NMDA’s direct receptor-mediated effects and reproducible calcium influx make it an essential reagent for advanced excitotoxicity research. For further protocol guidance or oxidative stress assay setup, refer to related internal resources or product documentation. NMDA is intended for scientific research use only.